Posts

Global Alopecia Treatment Industry Research Report

Alopecia Market

Alopecia Market

Market Summary

The Alopecia Market is expected to reach USD 12.99 Billion by 2026, according to a new report by Reports and Data. This can be mainly associated with the rising predominance of chronic disorders such as hyperthyroidism, hypothyroidism, acute stress disorder, lupus, and hypo pituitarism.

Moreover, increasing incidence of Hodgkin’s disease, Hashimoto’s disease, Addison’s disease, and celiac disease along with factors such as access to treatment quickly are expected to drive the market growth.

However, the high cost of treatment and adverse side effects is expected to restrain the growth. Also, changing lifestyle such as consumption of tobacco, an increase in the use of alcohol, and other associated products, growing stress levels, and the expanding population are expected to spur the market. Increasing disposable incomes coupled with expanding emphasis on aesthetic appearance are also likely to add to the demand for alopecia treatment worldwide.

Hair loss, also acknowledged as alopecia or baldness refers to a loss of hair from part of the head. The typical pattern of hair loss can vary from a small area to the entire body. Scarring or inflammation is not present. Hair loss in some people may cause psychological distress.

General types include female-pattern hair loss, male-pattern hair loss, alopecia areata, and a thinning of hair also known as telogen effluvium. The cause of male-pattern hair loss is a combination of male hormones and genetics, the purpose of female pattern hair loss is not clear, the use of alopecia areata is auto-immune, and the cause of telogen effluvium is mostly a psychological or physically stressful event.

The rising number of the introduction of new drugs, consumer disposable incomes, and the complementary initiatives taken by the relevant organizations namely, AHLA and NAAF, are the crucial factors for the North America region to account for the largest market share of 22.30% in 2018.

Key Coverage of the Report

Region and country wise statistics of Alopecia Market from the period 2016-2026. While 2016-2017 has been utilized as historical data, 2018 is considered the base year. 2019-2026 have been derived as forecasts.
Estimation of the market size along with historic and forecasted trend analysis.
Various Cure Types of Alopecia Market technique have been analyzed. Statistical analysis has been conducted on obtaining the individual share of these segments.
Regional up-coming Alopecia Market outlook.
Regional prevalence of the market has been mapped.
Demand and Supply GAP Analysis
Regional Competitors Pricing Strategy
Market share analysis of the top industry players
Strategic recommendations for the new entrants
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments.

Salient Trends of the Alopecia Market

The market is projected to grow at a CAGR of 1% in terms of value and reach USD 12.99 billion in 2026.
Based on disease type, the alopecia market is classified into androgenetic alopecia, alopecia areata (AA), and others. Androgenetic type led this market in 2018 with the largest revenue of USD 3.65 billion in 2018 and is expected to grow at a favorable rate over the forecast period.
Alopecia areata is an autoimmune skin disease identified by hair loss on the scalp, face, and other areas of the body. Alopecia areata is segmented into totalis, patchy, and universalis further.
The rising predominance of alopecia areata owing to autoimmune diseases such as diabetes, hyperthyroidism, and Down’s syndrome is expected to drive demand over the forecast period.
Increasing predominance coupled with rising awareness regarding aesthetic appeal and physical appearance is also assumed to drive market growth in the next few years.
Alopecia areata is expected to be the fastest-growing market with a CAGR of 5.2% during the forecast period.
Steroid injections may treat alopecia areata in the affected area, but these need to be continuously repeated to be effective. Hair loss is a common problem. The pattern of hair loss by age 50 affects about half of males and a quarter of females. About 1-2% of people develop alopecia areata at some point in time.
Male-Pattern Hair Loss (MPHL) or Androgenetic alopecia is associated with various medical conditions such as diabetes, coronary heart disease, obesity, prostate cancer, hypertension, and Polycystic Ovary Syndrome (PCOS).
Also, the availability of treatments such as oral treatments, licensed topical treatments involving the use of finasteride and minoxidil; and surgical procedures such as hair replacement and transplantation are expected to drive the market.
Laser treatments are also becoming common for non-invasive approach. Such non-invasive treatment approaches are also likely to drive the androgenetic segment.
The global Alopecia Market is growing at a rapid speed owing to the increase in stress and changed lifestyle.
The market can be classified into home care settings and dermatology clinics, based on application. Dermatology clinics account for the largest market share of 54.24% in 2018 and are anticipated to grow at a fruitful rate over the forecast period.
Dermatology clinics coupled with innovative technologies and prescription hair care products help many affected individuals fight their condition.
Consultation with dermatologists is regarded as the best option for the treatment, as they prescribe suitable medication or therapy for effective results. These factors are responsible for the high need for dermatology clinics for hair loss treatment.
On the other hand, treatment in home care settings is expected to grow at a rate of 5.1% during the forecast period.
Prescription medicine segment is anticipated to grow owing to increasing disposable income and quickly changing lifestyle. Finasteride and Corticosteroids are some of the majorly prescribed medications.
Based on the sales distribution, the market is segmented into prescription-based medications or treatment devices and Over the Counter (OTC).
Sale of prescription products account for the larger market share of 68.85% in 2018 and is estimated to reach USD 5.95 billion by 2026.
The OTC segment is expected to grow at a rate of 5.1% during the forecast period.
Increasing R&D efforts to improve treatments, FDA approvals obtained for certain products and strategic initiatives taken by the key players, are the primary competitive strategies paving the way for market expansion.
In April 2016, Johnson & Johnson announced the launch of a new global healthcare initiative to implement healthcare solutions, in Africa.
The developing prosperity of countries such as Indonesia, Taiwan, China, and India is inviting new international ventures in these countries thereby leading to the growth of various industries in the APAC region.

Companies considered and profiled in this market study

Cipla Inc., Johnson and Johnson AG, Transitions Hair Pty Ltd., Sun Pharmaceutical Industries Ltd., Merck & Co., Inc.,  Cirrus Hair Centers, Lexington International LLC,  Vita-Cos-Med Klett-Loch GmbH, Follica, Inc., and Capillus.

Market-O-Nomics

Rising demand for low-cost treatment, growing awareness regarding adverse effects of prescribed drugs, and the increasing availability of options are spurring the need for OTC products.
Moreover, a surge in the number of FDA-approved OTC products for hair loss treatments is additionally expanding their demand. Some of the FDA-approved OTC products for hair loss treatment are Oscar Blandi hair lift instant thickening and strengthening serum and Keranique hair regrowth system.
In 2018, the dominant gender segment for the alopecia market is women that accounts for the larger market share of 56.48%. The growing awareness amongst women about alopecia and the importance laid upon appearance by them are the key drivers of this segment.
Due to the predominance of a vast number of new entrants, established manufacturers, and suppliers in the market, the industry is extremely competitive.
Asia Pacific is forecasted to witness the fastest CAGR of 5.4% during the forecast period. A vast population suffering from alopecia and growing awareness about the available therapeutic options are the key growth drivers.
Economic development coupled with continually increasing per capita healthcare investment in emerging countries such as India, China, and Singapore is expected to create high growth opportunities.
Innovations and technological trends in treatment, evolving healthcare expenditures, and increased healthcare facilities are expected to drive the growth further.

Segments Covered in the report:

This report forecasts revenue growth at a global, regional & country level, and provides an analysis on the industry trends in each of the sub-segments from 2018 to 2026.

For the purpose of this study, Reports and Data have segmented the global Alopecia Market on the basis of Disease, Gender, application, Sales distribution and region:

Disease Outlook (Revenue, USD Million; 2016-2026)

Alopecia Areata
Androgenetic Alopecia
Others

Sales distribution Outlook (Revenue, USD Million; 2016-2026)

Prescriptions
OTC

Application Outlook (Revenue, USD Million; 2016-2026)

Homecare Settings
Dermatology Clinics

Gender Outlook (Revenue, USD Million; 2016-2026)

Female
Male

Regional Outlook (Revenue, USD Million; 2016-2026)

North America
U.S.
Europe
Germany
UK
Asia Pacific
China
India
Southeast Asia
Latin America
Brazil
Middle East & Africa

Source

Previous Posts

Global Alopecia Treatment Industry Research Report

Alopecia Market

Alopecia Market

Market Summary

The Alopecia Market is expected to reach USD 12.99 Billion by 2026, according to a new report by Reports and Data. This can be mainly associated with the rising predominance of chronic disorders such as hyperthyroidism, hypothyroidism, acute stress disorder, lupus, and hypo pituitarism.

Moreover, increasing incidence of Hodgkin’s disease, Hashimoto’s disease, Addison’s disease, and celiac disease along with factors such as access to treatment quickly are expected to drive the market growth.

However, the high cost of treatment and adverse side effects is expected to restrain the growth. Also, changing lifestyle such as consumption of tobacco, an increase in the use of alcohol, and other associated products, growing stress levels, and the expanding population are expected to spur the market. Increasing disposable incomes coupled with expanding emphasis on aesthetic appearance are also likely to add to the demand for alopecia treatment worldwide.

Hair loss, also acknowledged as alopecia or baldness refers to a loss of hair from part of the head. The typical pattern of hair loss can vary from a small area to the entire body. Scarring or inflammation is not present. Hair loss in some people may cause psychological distress.

General types include female-pattern hair loss, male-pattern hair loss, alopecia areata, and a thinning of hair also known as telogen effluvium. The cause of male-pattern hair loss is a combination of male hormones and genetics, the purpose of female pattern hair loss is not clear, the use of alopecia areata is auto-immune, and the cause of telogen effluvium is mostly a psychological or physically stressful event.

The rising number of the introduction of new drugs, consumer disposable incomes, and the complementary initiatives taken by the relevant organizations namely, AHLA and NAAF, are the crucial factors for the North America region to account for the largest market share of 22.30% in 2018.

Key Coverage of the Report

Region and country wise statistics of Alopecia Market from the period 2016-2026. While 2016-2017 has been utilized as historical data, 2018 is considered the base year. 2019-2026 have been derived as forecasts.
Estimation of the market size along with historic and forecasted trend analysis.
Various Cure Types of Alopecia Market technique have been analyzed. Statistical analysis has been conducted on obtaining the individual share of these segments.
Regional up-coming Alopecia Market outlook.
Regional prevalence of the market has been mapped.
Demand and Supply GAP Analysis
Regional Competitors Pricing Strategy
Market share analysis of the top industry players
Strategic recommendations for the new entrants
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments.

Salient Trends of the Alopecia Market

The market is projected to grow at a CAGR of 1% in terms of value and reach USD 12.99 billion in 2026.
Based on disease type, the alopecia market is classified into androgenetic alopecia, alopecia areata (AA), and others. Androgenetic type led this market in 2018 with the largest revenue of USD 3.65 billion in 2018 and is expected to grow at a favorable rate over the forecast period.
Alopecia areata is an autoimmune skin disease identified by hair loss on the scalp, face, and other areas of the body. Alopecia areata is segmented into totalis, patchy, and universalis further.
The rising predominance of alopecia areata owing to autoimmune diseases such as diabetes, hyperthyroidism, and Down’s syndrome is expected to drive demand over the forecast period.
Increasing predominance coupled with rising awareness regarding aesthetic appeal and physical appearance is also assumed to drive market growth in the next few years.
Alopecia areata is expected to be the fastest-growing market with a CAGR of 5.2% during the forecast period.
Steroid injections may treat alopecia areata in the affected area, but these need to be continuously repeated to be effective. Hair loss is a common problem. The pattern of hair loss by age 50 affects about half of males and a quarter of females. About 1-2% of people develop alopecia areata at some point in time.
Male-Pattern Hair Loss (MPHL) or Androgenetic alopecia is associated with various medical conditions such as diabetes, coronary heart disease, obesity, prostate cancer, hypertension, and Polycystic Ovary Syndrome (PCOS).
Also, the availability of treatments such as oral treatments, licensed topical treatments involving the use of finasteride and minoxidil; and surgical procedures such as hair replacement and transplantation are expected to drive the market.
Laser treatments are also becoming common for non-invasive approach. Such non-invasive treatment approaches are also likely to drive the androgenetic segment.
The global Alopecia Market is growing at a rapid speed owing to the increase in stress and changed lifestyle.
The market can be classified into home care settings and dermatology clinics, based on application. Dermatology clinics account for the largest market share of 54.24% in 2018 and are anticipated to grow at a fruitful rate over the forecast period.
Dermatology clinics coupled with innovative technologies and prescription hair care products help many affected individuals fight their condition.
Consultation with dermatologists is regarded as the best option for the treatment, as they prescribe suitable medication or therapy for effective results. These factors are responsible for the high need for dermatology clinics for hair loss treatment.
On the other hand, treatment in home care settings is expected to grow at a rate of 5.1% during the forecast period.
Prescription medicine segment is anticipated to grow owing to increasing disposable income and quickly changing lifestyle. Finasteride and Corticosteroids are some of the majorly prescribed medications.
Based on the sales distribution, the market is segmented into prescription-based medications or treatment devices and Over the Counter (OTC).
Sale of prescription products account for the larger market share of 68.85% in 2018 and is estimated to reach USD 5.95 billion by 2026.
The OTC segment is expected to grow at a rate of 5.1% during the forecast period.
Increasing R&D efforts to improve treatments, FDA approvals obtained for certain products and strategic initiatives taken by the key players, are the primary competitive strategies paving the way for market expansion.
In April 2016, Johnson & Johnson announced the launch of a new global healthcare initiative to implement healthcare solutions, in Africa.
The developing prosperity of countries such as Indonesia, Taiwan, China, and India is inviting new international ventures in these countries thereby leading to the growth of various industries in the APAC region.

Companies considered and profiled in this market study

Cipla Inc., Johnson and Johnson AG, Transitions Hair Pty Ltd., Sun Pharmaceutical Industries Ltd., Merck & Co., Inc.,  Cirrus Hair Centers, Lexington International LLC,  Vita-Cos-Med Klett-Loch GmbH, Follica, Inc., and Capillus.

Market-O-Nomics

Rising demand for low-cost treatment, growing awareness regarding adverse effects of prescribed drugs, and the increasing availability of options are spurring the need for OTC products.
Moreover, a surge in the number of FDA-approved OTC products for hair loss treatments is additionally expanding their demand. Some of the FDA-approved OTC products for hair loss treatment are Oscar Blandi hair lift instant thickening and strengthening serum and Keranique hair regrowth system.
In 2018, the dominant gender segment for the alopecia market is women that accounts for the larger market share of 56.48%. The growing awareness amongst women about alopecia and the importance laid upon appearance by them are the key drivers of this segment.
Due to the predominance of a vast number of new entrants, established manufacturers, and suppliers in the market, the industry is extremely competitive.
Asia Pacific is forecasted to witness the fastest CAGR of 5.4% during the forecast period. A vast population suffering from alopecia and growing awareness about the available therapeutic options are the key growth drivers.
Economic development coupled with continually increasing per capita healthcare investment in emerging countries such as India, China, and Singapore is expected to create high growth opportunities.
Innovations and technological trends in treatment, evolving healthcare expenditures, and increased healthcare facilities are expected to drive the growth further.

Segments Covered in the report:

This report forecasts revenue growth at a global, regional & country level, and provides an analysis on the industry trends in each of the sub-segments from 2018 to 2026.

For the purpose of this study, Reports and Data have segmented the global Alopecia Market on the basis of Disease, Gender, application, Sales distribution and region:

Disease Outlook (Revenue, USD Million; 2016-2026)

Alopecia Areata
Androgenetic Alopecia
Others

Sales distribution Outlook (Revenue, USD Million; 2016-2026)

Prescriptions
OTC

Application Outlook (Revenue, USD Million; 2016-2026)

Homecare Settings
Dermatology Clinics

Gender Outlook (Revenue, USD Million; 2016-2026)

Female
Male

Regional Outlook (Revenue, USD Million; 2016-2026)

North America
U.S.
Europe
Germany
UK
Asia Pacific
China
India
Southeast Asia
Latin America
Brazil
Middle East & Africa

Source

Previous Posts

Alopecia Treatment Market

Alopecia Treatment Market

Global Alopecia Treatment (Hair Loss) Market– Industry Trends and Forecast to 2026

The Global Alopecia Treatment (Hair Loss) Market is expected to rise from its initial estimated value of USD 8.21 billion in 2018 to an estimated value of USD 12.40 billion by 2026 registering a CAGR of 5.3% in the forecast period of 2019-2026. This rise in the market can be attributed to the rising geriatric population along with high demand for surgical hair transplant and changing lifestyle.

Market Definition: Global Alopecia Treatment (Hair Loss) Market

Alopecia areata is a medical condition which is a type of alopecia which attacks the hair follicles causes the breakage or fall of hair leading to complete baldness. The patient suffering from alopecia areata, their scalp becomes patchy, diffused and confluent pattern leading the hair fall initially and later spread over the entire scalp termed as alopecia totalis or entire epidermis.

Alopecia areata is an autoimmune hair loss on the scalp or on the body and commonly it shows a form of solitary and multiple patches of alopecia.

Market Drivers:

  • The rising geriatric population along with high demand for surgical hair transplant will boost the market
  • Changing lifestyle along with increase in stress level among working-class population can fuel the growth of the market

Market Restraints:

  • High cost of alopecia treatment (hair loss) is acting as a major restraint for the market
  • Side effects/allergic reactions by treatment also acting as a major market restraint.

Segmentation: Global Alopecia Treatment (Hair Loss) Market

  • By Disease Type
    • Androgenic Alopecia
    • Alopecia Areata
    • Ciatricial Alopecia
    • Traction Alopecia
    • Alopecia Totalis
  • By Drug Type
    • Minoxidil
    • Finasteride
    • Cyclosporine
    • Others
  • By Gender
    • Male
    • Female
  • By Route of Administration
  • Oral
    • Topical
    • Injectable
  • By Distribution Channel
    • Hospital
    • Retail Pharmacies
    • Online Pharmacies
  • By Geography
    • North America
      • US
      • Canada
      • Mexico
    • South America
      • Brazil
      • Argentina
      • Rest of South America
    • Europe
      • Germany
      • France
      • United Kingdom
      • Italy
      • Spain
      • Russia
      • Turkey
      • Belgium
      • Netherlands
      • Switzerland
      • Rest of Europe
    • Asia-Pacific
      • Japan
      • China
      • South Korea
      • India
      • Australia
      • Singapore
      • Malaysia
      • Indonesia
      • Thailand
      • Philippines
      • Rest of Asia-Pacific
    • Middle East and Africa
      • South Africa
      • Egypt
      • Saudi Arabia
      • United Arab Emirates
      • Israel
      • Rest of Middle East and Africa

Key Developments in the Market:

  • In January 2018, Concert Pharmaceuticals, Inc. announced U.S. FDA granted Fast Track designation for CTP-543, a novel, oral Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe alopecia areata, a disease which attacks the hair follicles, leading to hair loss.
  • In May 2018, Histogen, Inc (U.S.) announced that received approval to Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) to study its lead product in female diffuse hair loss.
  • In March 2017, Perrigo Perrigo Company PLC (U.S.) announced the launch of over-the-counter Women’s Rogaine, which helps to regrow hair on top of the scalp.

Competitive Analysis: Global Alopecia Treatment (Hair Loss) Market

The global alopecia treatment (hair loss) market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of alopecia treatment (hair loss) market for global, Europe, North America, Asia Pacific, South America and Middle East & Africa.

Key Market Competitors: Global Alopecia Treatment (Hair Loss) Market

Few of the major market competitors currently working in the alopecia treatment (hair loss) market are Cipla, Viviscal, Dr. Reddy’s Laboratories Ltd., Regaine, Merck & Co., Inc, Ranbaxy Laboratories Ltd, Phyto – Alès Groupe, Kirkland Signature, Vitabiotics, Nanogen, Alpecin – Dr. Kurt Wolff GmbH & Co. KG, Rogaine – Johnson and Johnson, Histogen, Inc., Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., HCell Inc., GlaxoSmithKline plc., Perrigo Company PLC. and Daiichi Sankyo, Inc.

Research Methodology: Global Alopecia Treatment (Hair Loss) Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report.

The key research methodology used by DBMR Research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents:

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report:

  • Current and future of global alopecia treatment (hair loss) market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players

Customization of the Report:

  • All segmentation provided above in this report is represented at country level
  • All products covered in the market, product volume and average selling prices will be included as customizable options which may incur no or minimal additional cost (depends on customization)

Global Alopecia Treatment (Hair Loss) Market– Industry Trends and Forecast to 2026

Source

Recent Posts

Alopecia Treatment Market

Alopecia Treatment Market

Global Alopecia Treatment Market Size Share Forecast 2025

Alopecia also called as hair loss or baldness is a very common condition affecting people across the globe. Alopecia can affect people of all gender and at any stage of life, it generally it affects mid-aged generation. For instance, according the data published by Arch Argent Pediatr in 2017, the prevalence of Alopecia areata is high in the age group of 10 and 25 years and around 60% of people under these age group suffer from Alopecia areata.

Market Dynamics

Product launches, approvals, and a robust pipeline of novel products is expected to be the major driver of the growth of the global alopecia treatment market. For instance, in 2016, Cellmid Limited, a wholly-owned subsidiary, Advangen Limited launched new hair loss product évolis in U.S. market.

In May 2018, Histogen, Inc., received the approval of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to study its lead product Hair Stimulating Complex (HSC660) in female diffuse hair loss. HSC660 is an investigational injectable treatment for alopecia and is expected to get FDA approval in the near future. Key players in the market are engaged in strategic collaborations for increasing geographic presence in the market.

For instance, in May 2018, Cellmid Limited signed a collaborative agreement with Beijing Fukangren Bio-pharm Tech Co Ltd. for distribution of its product in the Peoples Republic of China. Furthermore, the increasing prevalence of alopecia worldwide is expected to drive the growth of the market.

According to the data published by National Center for Biotechnology Information (NCBI), in 2015, androgenetic alopecia is a most prevalent autoimmune disorder and the second most prevalent hair loss disorder and around 2% population worldwide is suffering from androgenetic alopecia.

Key features of the study:

• This report provides in-depth analysis of alopecia treatment market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR %) for the forecast period (2018 – 2026), considering 2017 as the base year

• It elucidates potential revenue opportunity across different segments and explains the attractive investment proposition matrix for this market

• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players

• It profiles leading players in the global alopecia treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies, and future plans

• Key companies covered as a part of this study include Histogen, Inc., Aclaris Therapeutics, Inc., Concert Pharmaceuticals, Inc., HCell Inc., GlaxoSmithKline plc., Daiichi Sankyo, Inc., Cipla Limited, and others.

• Insights from this report would allow marketers and the management authorities of the companies to make an informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics

• The global alopecia treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the alopecia treatment market

Detailed Segmentation:

• Global Alopecia Treatment Market, By Disease Type :

o Androgenic Alopecia
o Alopecia Areata
o Ciatricial Alopecia
o Traction Alopecia
o Alopecia Totalis

• Global Alopecia Treatment Market, By Drug Type:

o Vasodilators
o Minoxidil
o 5-Alpha Reductase Inhibitors
o Finasteride
o Corticosteroids
o Immunosuppressants
o Cyclosporine
o Others
o Others

• Global Alopecia Treatment Market, By Gender:

o Male
o Female

• Global Alopecia Treatment Market, By Route of Administration:

o Oral
o Topical
o Injectable

• Global Alopecia treatment market, By Distribution Channel:

o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies

• Global Alopecia treatment market, By Geography:

Global Alopecia Treatment Market Size Share Forecast 2025

Source

Recent Posts

hair loss and stem cells

Platelet Rich Plasma and Stem Cell Alopecia Treatment

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size And Forecast

The Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2020 to 2027.

The Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market report provide a holistic evaluation of the market for the forecast period (2018–2027). The report comprises of various segments as well an analysis of the trends and factors that are playing a substantial role in the market.

These factors; the market dynamics, involves the drivers, restraints, opportunities and challenges through which the impact of these factors in the market are outlined. The drivers and restraints are intrinsic factors whereas opportunities and challenges are extrinsic factors of the market. The Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market study provide an outlook on the development of the market in terms of revenue throughout the prognosis period.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Scope of the Report

This report provides an all-inclusive environment of the analysis for the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market. The market estimates provided in the report are the result of in-depth secondary research, primary interviews and in-house expert reviews. These market estimates have been considered by studying the impact of various social, political and economic factors along with the current market dynamics affecting the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market growth

Along with the market overview, which comprises of the market dynamics the chapter includes Porter’s Five Forces analysis which explains the five forces: namely buyers bargaining power, suppliers bargaining power, the threat of new entrants, threat of substitutes, and degree of competition in the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market.

It explains the various participants, such as system integrators, intermediaries and end-users within the ecosystem of the market. The report also focuses on the competitive landscape of the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Competitive Landscape

The market analysis entails a section solely dedicated for major players in the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market wherein our analysts provide an insight to the financial statements of all the major players along with its key developments product benchmarking and SWOT analysis. The company profile section also includes a business overview and financial information. The companies that are provided in this section can be customized according to the client’s requirements.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market, By Product

• Androgenic Alopecia
• Congenital Alopecia
• Cicatricial Or Scarring Alopecia

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market, By Application

• Hospital
• Dermatology Clinic
• Other

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market, By Geography

• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Rest of Asia Pacific
• Rest of the World
o Latin America
o Middle East & Africa

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market, Key Players

• Kerastem
• Eclipse
• Stemcell Technologies
• RepliCel Life Sciences
• Regen Lab SA
• Histogen
• Glofinn Oy.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Research Methodology

The research methodology is a combination of primary research secondary research and expert panel reviews. Secondary research includes sources such as press releases company annual reports and research papers related to the industry. Other sources include industry magazines, trade journals, government websites and associations were can also be reviewed for gathering precise data on opportunities for business expansions in Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market.

Primary research involves telephonic interviews various industry experts on acceptance of appointment for conducting telephonic interviews sending questionnaire through emails (e-mail interactions) and in some cases face-to-face interactions for a more detailed and unbiased review on the Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market, across various geographies.

Primary interviews are usually carried out on an ongoing basis with industry experts in order to get recent understandings of the market and authenticate the existing analysis of the data. Primary interviews offer information on important factors such as market trends market size, competitive landscape growth trends, outlook etc.

These factors help to authenticate as well as reinforce the secondary research findings and also help to develop the analysis team’s understanding of the market.

Reasons to Purchase this Report:

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Size And Forecast

Source

Previous Posts

CTP-543 Phase 3 Trials in Alopecia Areata

Clinical Trial of CTP-543Clinical Trial of CTP-543

Concert Pharmaceuticals Releases Additional Data from Phase 2 Clinical Trial of CTP-543 in Alopecia Areata

Concert Pharmaceuticals, Inc. today released new data analyses from its Phase 2 dose-ranging clinical trial of its investigational agent CTP‑543 for the treatment of moderate-to-severe alopecia areata.

The results were selected as an oral presentation at the Late-Breaking Research Program at the American Academy of Dermatology (AAD) Annual Meeting; however, the in-person meeting, originally scheduled for March 21, 2020, in Denver, was converted to a virtual meeting. The corresponding abstract was published by AAD in connection with the virtual meeting.

The data analyses released by Concert build on the previously-reported Phase 2 primary efficacy analysis which showed that administration of 8 mg twice daily and 12 mg twice-daily doses of CTP-543 for 24 weeks produced a statistically significantly greater number of responders compared to placebo.

A responder was defined as a ≥ 50% relative reduction in the Severity of Alopecia Tool (SALT) score at Week 24 compared to baseline. In the new analyses, statistically significant results were reported for the 8 mg and 12 mg twice-daily doses at more stringent response thresholds, which may be more clinically meaningful to patients, and positive findings were reported for clinician and patient-reported outcome measures of scalp hair loss.

“We believe that these data from our Phase 2 dose-ranging study set a new benchmark for clinical efficacy in treating alopecia areata and provide important information to inform our planned Phase 3 trials with CTP-543.

Since both the 8 mg and 12 mg twice-daily doses resulted in statistically significant improvement in SALT scores compared to placebo and exhibited a generally well-tolerated safety profile, we plan to assess both doses in our Phase 3 program,” said James V. Cassella, Ph.D., Chief Development Officer of Concert Pharmaceuticals. “Importantly, we would like to thank the alopecia areata patients for their participation in this study, as well as the clinical investigators and research staff for their significant efforts to support the development of CTP-543.”

Key new findings further highlight the positive efficacy results in the Phase 2 study, including:

  • Meaningful hair regrowth: At Week 24, 26% and 42% of patients who received CTP-543 in the 8 and 12 mg twice-daily cohorts, respectively, achieved an absolute SALT score ≤ 20 (p <0.05 vs. placebo), indicating a clinically-meaningful 80 per cent or greater scalp hair present. In addition, 36% of patients in the 12 mg twice-daily cohort achieved an absolute SALT score ≤ 10 (p <0.05 vs. placebo) at Week 24.
  • Clinical Global Impression of Improvement: Data from the Clinician Global Impression of Improvement scale showed 75% of clinicians rated the response in the 12 mg twice-daily cohort and 61% of clinicians rated the response in the 8 mg twice-daily cohort as “much improved” or “very much improved” at Week 24. For both doses, there was a statistically significant difference from placebo (p <0.001).
    • Similarly, previously-reported data from the Phase 2 trial for the Patient Global Impression of Improvement scale showed 78% of patients receiving 12 mg twice daily and 58% of patients receiving 8 mg twice-daily rated their alopecia areata as “much improved” or “very much improved” at Week 24. For both doses, there was a statistically significant difference from placebo (p <0.001).

In Phase 2 dose-ranging trial, the most common (≥10%) side effects in the 8 mg or 12 mg CTP-543 dose groups were headache, nasopharyngitis, upper respiratory tract infection, acne, nausea and low-density lipoprotein increase. One serious adverse event of facial cellulitis was reported in the 12 mg dose group as possibly related to treatment. After a brief dosing interruption, treatment was continued, and this patient completed the trial. No thromboembolic events were reported during the trial.

Slides summarizing the new analyses are available in the Scientific Presentations section of Concert’s website.

About the Phase 2 Trial Design of CTP-543 in Alopecia Areata

The Phase 2 trial was a double-blind, randomized, placebo-controlled, sequential dose trial to evaluate the safety and efficacy of CTP-543 in adult patients with moderate-to-severe alopecia areata. A total of 149 patients were randomized to receive one of three doses of CTP-543 (4 mg, 8 mg or 12 mg) or placebo, administered twice-daily. The primary outcome measure utilized the SALT score after 24 weeks of dosing. The average baseline SALT score across all patients was approximately 88%, where 0% is no scalp hair loss and 100% represents total scalp hair loss. All patients who completed 24 weeks of treatment in the 12 mg dosing cohort had the opportunity to continue in a separate extension study to evaluate long-term safety and efficacy of CTP-543.

Previously-reported data from the Phase 2 trial demonstrated a relative reduction in overall SALT scores from baseline at Week 24, the primary efficacy endpoint of the study. In the 12 mg twice-daily cohort, 58% of patients achieving a ≥ 50% relative reduction in their overall SALT score from baseline compared to 9% for placebo (p <0.001). In the 8 mg twice-daily cohort, 47% of patients achieved the primary endpoint compared to placebo (p <0.001).

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted Fast Track designation for CTP-543 for the treatment of alopecia areata. The Company intends to advance CTP-543 into Phase 3 evaluation in the fourth quarter of 2020.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect approximately 700,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. The onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017.

The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

Concert Pharmaceuticals Releases Additional Data from Phase 2 Clinical Trial of CTP-543 in Alopecia Areata

1 Benigno M. Clinical, Cosmetic and Investigational Dermatology. 2020.

 

Previous Posts

PRP Workshop To Enhance Hair Restoration

Global Platelet Rich Plasma Treatment

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Research Report 2020

Stem cell and platelet-rich plasma (PRP) therapies are considered as regenerative or biomedicines. They are minimally invasive and hence reduce the need for surgery. These therapies help stimulate, rebuild, and strengthen hair regrowth, instead of removing damaged tissue from the scalp.

Novel therapies for alopecia are preferred by dermatologists and patients over conventional drugs such as corticosteroids. Greater preference for these therapies arises from efficient and faster hair regrowth as compared to other corticosteroid treatments.

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency.

The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Platelet Rich Plasma and Stem Cell Alopecia Treatment market in 2020.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

This report also analyses the impact of Coronavirus COVID-19 on the Platelet Rich Plasma and Stem Cell Alopecia Treatment industry.

Based on our recent survey, we have several different scenarios about the Platelet Rich Plasma and Stem Cell Alopecia Treatment YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019.

The market size of Platelet Rich Plasma and Stem Cell Alopecia Treatment will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
QY Research has recently curated a research report titled, Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Research Report 2020. The report is structured on primary and secondary research methodologies that derive historic and forecast data.

The global Platelet Rich Plasma and Stem Cell Alopecia Treatment market is growing remarkably fast and is likely to thrive in terms of volume and revenue during the forecast period. Readers can gain insight into the various opportunities and restraints shaping the market. The report demonstrates the progress and bends that will occur during the forecast period.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Drivers and Restrains

The research report has incorporated the analysis of different factors that augment the market’s growth. It constitutes trends, restraints, and drivers that transform the market in either a positive or negative manner. This section also provides the scope of different segments and applications that can potentially influence the market in the future.

The detailed information is based on current trends and historic milestones. This section also provides an analysis of the volume of sales about the global market and also about each type from 2015 to 2026.

This section mentions the volume of sales by region from 2015 to 2026. Pricing analysis is included in the report according to each type from the year 2015 to 2026, manufacturer from 2015 to 2020, region from 2015 to 2020, and global price from 2015 to 2026.

A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market experts opinions have been taken to understand the market better.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Segment Analysis

The research report includes specific segments such as application and product type. Each type provides information about the sales during the forecast period of 2015 to 2026. The application segment also provides revenue by volume and sales during the forecast period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region.

Analysts have studied the data of revenue, sales, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market.

The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.

Following are the segments covered by the report are:

Androgenic Alopecia
Congenital Alopecia
Cicatricial Or Scarring Alopecia

By Application:

Hospital
Dermatology Clinic
Other

Key Players:

The Key manufacturers that are operating in the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market are:

Kerastem
Eclipse
Regen Lab SA
Stemcell Technologies
RepliCel Life Sciences
Histogen
Glofinn Oy.

Competitive Landscape

The analysts have provided a comprehensive analysis of the competitive landscape of the global Platelet Rich Plasma and Stem Cell Alopecia Treatment market with the company market structure and market share analysis of the top players.

The innovative trends and developments, mergers and acquisitions, product portfolio, and new product innovation to provide a dashboard view of the market, ultimately providing the readers accurate measure of the current market developments, business strategies, and key financials.

Global Platelet Rich Plasma and Stem Cell Alopecia Treatment Market Research Report 2020

Source

Previous Posts

Alopecia Treatment Market

Alopecia Market Business Opportunities 2026

Alopecia Market Business Opportunities 2026

A new research study has been presented by UpMarketResearch.com offering a comprehensive analysis on the Global Alopecia (Hair Loss Treatment) Market where user can benefit from the complete market research report with all the required useful information about this market.

The report discusses all major market aspects with expert opinion on current market status along with historic data. This market report is a detailed study on the growth, investment opportunities, market statistics, growing competition analysis, major key players, industry facts, important figures, sales, prices, revenues, gross margins, market shares, business strategies, top regions, demand, and developments.

 

The Alopecia (Hair Loss Treatment) Market report provides a detailed analysis of the global market size, regional and country-level market size, segment growth, market share, competitive landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunity analysis, strategic market growth analysis, product launches, and technological innovations.

Get a Free Sample Copy of the Alopecia (Hair Loss Treatment) Market Report with Latest Industry Trends @ https://www.upmarketresearch.com/home/requested_sample/105857

Major Players Covered in this Report are:

Shiseido
Rohto
Unilever
Taisho
Angfa
LOreal
Kaminomoto
Merck
Yanagiya Honten
Amorepacific
Procter & Gamble
Himalaya
Gerolymatos International
Merz Pharma
Leader Teck
Vasu Healthcare
VLCC
Ales Group
Shanxi Ante
Wansheng Pharmaceutical
Advanced Skin and Hair
Humanwell Healthcare
Topfond
Lifes2good
Bawang
YNK Pharmaceutical
Apollo
Jingxiutang
Rogaine
Marico

Global Alopecia (Hair Loss Treatment) Market Segmentation

This market has been divided into Types, Applications, and Regions. The growth of each segment provides an accurate calculation and forecast of sales by Types and Applications, in terms of volume and value for the period between 2020 and 2026. This analysis can help you expand your business by targeting qualified niche markets. Market share data is available on the global and regional level.

Regions covered in the report are North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. Research analysts understand the competitive strengths and provide competitive analysis for each competitor separately.

By Types:

Shampoos and Conditioners
Medicine Product

By Applications:

Men
Women

Global Alopecia (Hair Loss Treatment) Market Regions and Countries Level Analysis

 

Regional analysis is a highly comprehensive part of this report. This segmentation sheds light on the sales of the Alopecia (Hair Loss Treatment) on regional- and country-level. This data provides a detailed and accurate country-wise volume analysis and region-wise market size analysis of the global market.

The report offers an in-depth assessment of the growth and other aspects of the market in key countries including the US, Canada, Mexico, Germany, France, the UK, Russia, Italy, China, Japan, South Korea, India, Australia, Brazil, and Saudi Arabia. The competitive landscape chapter of the global market report provides key information about market players such as company overview, total revenue (financials), market potential, global presence, Alopecia (Hair Loss Treatment) sales and revenue generated, market share, prices, production sites and facilities, products offered, and strategies adopted.

This study provides Alopecia (Hair Loss Treatment) sales, revenue, and market share for each player covered in this report for a period between 2016 and 2020.

Alopecia Market Business Opportunities 2026

Source

Previous Posts

 

Male Androgenetic Alopecia

Alopecia Augmented Expansion to be Registered by 2019-2025

Alopecia Augmented Expansion to be Registered by 2019-2025

Alopecia (Hair Loss Treatment) Market 2018: Global Industry Insights by Global Players, Regional Segmentation, Growth, Applications, Major Drivers, Value and Foreseen till 2024

The recently published research report sheds light on critical aspects of the global Alopecia (Hair Loss Treatment) market such as vendor landscape, competitive strategies, market drivers and challenges along with the regional analysis.

The report helps the readers to draw a suitable conclusion and clearly understand the current and future scenario and trends of global Alopecia (Hair Loss Treatment) market.

The research study comes out as a compilation of useful guidelines for players to understand and define their strategies more efficiently in order to keep themselves ahead of their competitors.

The report profiles leading companies of the global Alopecia (Hair Loss Treatment) market along with the emerging new ventures who are creating an impact on the global market with their latest innovations and technologies.

The recently published study includes information on key segmentation of the global Alopecia (Hair Loss Treatment) market on the basis of type/product, application and geography (country/region). Each of the segments included in the report is studies in relations to different factors such as market size, market share, value, growth rate and other quantitate information.

The competitive analysis included in the global Alopecia (Hair Loss Treatment) market study allows their readers to understand the difference between players and how they are operating amounts themselves on a global scale.

The research study gives deep insight into the current and future trends of the market along with the opportunities for the new players who are in the process of entering global Alopecia (Hair Loss Treatment) market.

Market dynamic analysis such as market drivers, market restraints is explained thoroughly in the most detailed and easiest possible manner. The companies can also find several recommendations to improve their business on a global scale.

The readers of the Alopecia (Hair Loss Treatment) Market report can also extract several key insights such as the market size of varies products and application along with their market share and growth rate. The report also includes information for the next five years as forested data and past five years as historical data and the market share of the several key information.

Make An Enquiry About This Report @ https://www.marketresearchhub.com/enquiry.php?type=E&repid=2578095&source=atm

Global Alopecia (Hair Loss Treatment) Market by Companies:

The company profile section of the report offers great insights such as market revenue and market share of global Alopecia (Hair Loss Treatment) market. Key companies listed in the report are:

The following manufacturers are covered:

Shiseido
Rohto
Unilever
Taisho
Angfa
LOreal
Kaminomoto
Merck
Yanagiya Honten
Amorepacific
Procter & Gamble
Himalaya
Gerolymatos International
Merz Pharma
Leader Teck
Vasu Healthcare
VLCC
Ales Group
Shanxi Ante
Wansheng Pharmaceutical
Advanced Skin and Hair
Humanwell Healthcare
Topfond
Lifes2good
Bawang
YNK Pharmaceutical
Apollo
Jingxiutang
Rogaine
Marico

Segment by Regions

North America
Europe
China
Japan
Southeast Asia
India

Segment by Type

Shampoos and Conditioners
Medicine Product

Segment by Application

Men
Women

Global Alopecia (Hair Loss Treatment) Market by Geography:

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)
Europe (Turkey, Germany, Russia UK, Italy, France, etc.)
North America (the United States, Mexico, and Canada.)
South America (Brazil etc.)
The Middle East and Africa (GCC Countries and Egypt.)

Alopecia Augmented Expansion to be Registered by 2019-2025

Source

Previous Posts

 

Alopecia Treatment Market

Androgenetic Alopecia Pipeline Insight 2020

Androgenetic Alopecia – Pipeline Insight 2020

Androgenetic Alopecia pipeline insight, 2020 report outlays comprehensive insights of present clinical development scenario and growth prospects across the androgenetic alopecia market. A detailed picture of the androgenetic alopecia pipeline landscape is provided, which includes the disease overview and androgenetic alopecia treatment guidelines.

The assessment part of the report embraces in-depth androgenetic alopecia commercial assessment and clinical assessment of the androgenetic alopecia pipeline products from the pre-clinical developmental phase to the marketed phase.

In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, androgenetic alopecia collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

The Report Provides Insights into:

All of the companies that are developing therapies for the treatment of androgenetic alopecia with aggregate therapies developed by each company for the same.
Different therapeutic candidates segmented into early-stage, mid-stage and late stages of development for the androgenetic alopecia treatment.
Androgenetic alopecia key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of androgenetic alopecia market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, sec filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.

Androgenetic Alopecia Analytical Perspective

In-Depth Androgenetic Alopecia Commercial Assessment of Products

This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.

Androgenetic alopecia clinical assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and moa type across this indication.

Scope of the report

The androgenetic alopecia report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and moa type for androgenetic alopecia across the complete product development cycle, including all clinical and nonclinical stages.
It comprises of detailed profiles of androgenetic alopecia therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
Detailed androgenetic alopecia research and development progress and trial details, results wherever available, are also included in the pipeline study.
Coverage of dormant and discontinued pipeline projects along with the reasons if available across androgenetic alopecia.

Report Highlights

A better understanding of disease pathogenesis contributing to the development of novel therapeutics for androgenetic alopecia.
in the coming years, the androgenetic alopecia market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies and academics that are working to assess challenges and seek opportunities that could influence androgenetic alopecia R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
A detailed portfolio of major pharma players who are involved in fueling the androgenetic alopecia treatment market. Several potential therapies for androgenetic alopecia are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the androgenetic alopecia market size in the coming years.
The in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of androgenetic alopecia ) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Key Questions

What are the current options for androgenetic alopecia treatment?
How many companies are developing therapies for the treatment of androgenetic alopecia?
What are the principal therapies developed by these companies in the industry?
How many therapies are developed by each company for the treatment of androgenetic alopecia?
How many androgenetic alopecia emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of androgenetic alopecia?
Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
What are the key collaborations (industry-industry, industry-academia), mergers and acquisitions, and major licensing activities that will impact androgenetic alopecia market?
Which are the dormant and discontinued products and the reasons for the same?
What is the unmet need for current therapies for the treatment of androgenetic alopecia?
What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing androgenetic alopecia therapies?
What are the clinical studies going on for androgenetic alopecia and their status?
What are the results of the clinical studies and their safety and efficacy?
What are the key designations that have been granted for the emerging therapies for androgenetic alopecia?
How many patents are granted and pending for the emerging therapies for the treatment of androgenetic alopecia?

Androgenetic Alopecia – Pipeline Insight 2020

Source

Previous Posts

Positive CTP-543 Results from Phase 2 Alopecia Areata Trial

Open Label Trial of CTP-543 in Patients with Alopecia Areata

Concert Pharmaceuticals Successfully Completes Open Label Trial of CTP-543 in Patients with Alopecia Areata

Concert Pharmaceuticals, Inc. today announced that it has completed its open label trial evaluating 8 mg twice-daily compared to 16 mg once-daily dosing of CTP-543 in patients with moderate-to-severe alopecia areata. Results in the 8 mg twice-daily arm were consistent with the previously-reported 8 mg twice-daily results from the Company’s Phase 2 trial of CTP-543. Treatment was generally well tolerated in both arms of the study. All but one of the patients who completed this trial have elected to continue in an open-label long-term extension study. The Company expects to report findings from the study at a future medical meeting

“Based on the results observed, the twice-daily regimen is preferred, and we intend to utilize it in our clinical development program for CTP-543 going forward,” said Roger Tung, Ph.D., President and Chief Executive Officer of Concert Pharmaceuticals. “We believe that the findings from our dose regimen studies may be valuable to CTP-543’s intellectual property portfolio and therefore are not disclosing additional data from this study at this time.”

The dose regimen trial (NCT03811912) was a randomized, multi-center study to evaluate the efficacy and tolerability of once-daily versus twice-daily oral dosing of CTP-543, in adult patients with moderate-to-severe alopecia areata. Fifty-seven patients in the trial were randomized to receive CTP-543 either 8 mg twice-daily or 16 mg once-daily over a 24-week treatment period. The trial measured the relative change in Severity of Alopecia Tool (SALT) score between Week 24 and baseline.

Data from the Company’s Phase 2 trials will support an end of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to review and discuss the Company’s registration pathway for CTP-543 for the treatment of alopecia areata. The Company expects to meet with the FDA and initiate Phase 3 testing in 2020.

About CTP-543 and Alopecia Areata

CTP-543 is an oral selective inhibitor of Janus kinases JAK1 and JAK2. The FDA has granted Fast Track designation for CTP-543 for the treatment of alopecia areata.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 650,000 Americans at any given time1. The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently no drugs approved by the FDA for the treatment of alopecia areata.

The FDA selected alopecia areata as one of eight new disease areas that it focused on under its Patient-Focused Drug Development Initiative (PFDDI) in 2016-2017. The goal of the PFDDI is to bring patient perspectives into an earlier stage of product development. Following the FDA’s Patient-Focused Drug Development meeting held in September 2017 on alopecia areata, the FDA summarized the input shared by patients and patient representatives in a Voice of the Patient report. Additional information on the PFDDI is available online.

About Concert

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.

Concert Pharmaceuticals Successfully Completes Open Label Trial of CTP-543 in Patients with Alopecia Areata

Source

Previous Posts